2 results
Approved WMOWill not start
To evaluate the safety, tolerability and efficacy of IZD334 to reduce CRP in cardiovascular high-risk patients.
Approved WMORecruiting
PRIMARY OBJECTIVES*Rx-induction: Comparison of the 3 year EFS rate of 2 induction regimens, GPOH and RAPID COJEC, in patients with high-risk neuroblastoma.*Rx-HDC: Comparison of the 3 year EFS rate from randomization of single HDC with Bu-Mel versus…